Início › Mieloma Múltiplo › Carolina do Norte › Charlotte
Ensaios clínicos de Mieloma Múltiplo em Charlotte, NC
21 estudos para Mieloma Múltiplo estão buscando participantes em locais em Charlotte e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecrutandoFase 3
- Research Site, Charlotte
- Research Site, Charlotte
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecrutandoFase 1
- Levine Cancer Institute, Charlotte
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RecrutandoFase 2
- Atrium Health, Charlotte
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecrutandoFase 3
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecrutandoFase 4
- Levine Cancer Institute, Charlotte
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 1/2
- Atrium Health Levine Cancer Institute, Charlotte
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecrutandoFase 2
- Atrium Health's Levine Cancer Institute, Charlotte
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RecrutandoFase 3
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RecrutandoFase 1/2
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RecrutandoFase 3
- Novant Health Cancer Institute, Charlotte
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RecrutandoFase 1
- Atrium Health, Levine Cancer Institute, Charlotte
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecrutandoFase 1/2
- Research Site, Charlotte
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecrutandoFase 3
- Research Site, Charlotte
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RecrutandoFase 1/2
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
Pre-malignant States to Hematologic Malignancies in Firefighters
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Levine Cancer Institute, Charlotte
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Atrium Health Levine Cancer, Charlotte
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RecrutandoFase 3
- Levine Cancer Institute, Charlotte
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RecrutandoFase 2
- Levine Cancer Institute, Charlotte
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RecrutandoFase 1/2
- Levine Cancer Institute, Charlotte
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RecrutandoFase 3
- GSK Investigational Site, Charlotte
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RecrutandoFase 1
- Levine Cancer Institute, Charlotte
Ensaios de Mieloma Múltiplo em outras cidades
- New York City, NY60 estudos
- Boston, MA42 estudos
- Atlanta, GA41 estudos
- Houston, TX38 estudos
- Durham, NC37 estudos
- Nashville, TN32 estudos
- Denver, CO27 estudos
- Rochester, MN24 estudos
- St. Louis, MO24 estudos
- Columbus, OH24 estudos
- Baldwin Park, CA23 estudos
- Chicago, IL22 estudos
Outros estudos em Charlotte
- Câncer (todos os tipos)27 estudos
- Câncer de Mama22 estudos
- Câncer de Pulmão de Não Pequenas Células19 estudos
- Leucemia Mieloide Aguda16 estudos
- Obesidade16 estudos
- Sobrepeso15 estudos
- Câncer Colorretal13 estudos
- Câncer de Ovário12 estudos
- Câncer Metastático11 estudos
- Insuficiência Cardíaca11 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço10 estudos
- DPOC9 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.